-
How mRNA technology is altering vaccine treatments
Back in January, just one month after Moderna’s COVID-19 vaccine was authorized for emergency use, fears about a contagious variant strain began to grip the nation – and scientists at Moderna immediately realized this could be a threat. “We didn’t think we had time to wait,” said Dr. Stephen Hoge, president of the company. “We thought, ‘If we don’t start now, then by the time we get to the fall, we won’t have an updated vaccine in case those variants really become a significant concern and start reinfecting people.” As millions of doses rolled off the manufacturing line at
-
Establishment of a COVID-19 mRNA vaccine technology transfer hub to scale up global manufacturing
WHO and its partners are seeking to expand the capacity of low- and middle-income countries (LMICs) to produce COVID-19 vaccines and scale up manufacturing to increase global access to these critical tools to bring the pandemic under control. WHO will facilitate the establishment of one (or more, as appropriate) technology transfer1 hub(s) that will use a hub and spoke model (REF) to transfer a comprehensive technology package and provide appropriate training to interested manufacturers in LMICs. This initiative will initially prioritize the mRNA-vaccine technology2 but could expand to other technologies in the future. The intention is for these
